Positive Long-Term Data For BENLYSTA (formerly LYMPHOSTAT-B(R)) In Patients With Active Lupus
Main Category: LupusArticle Date: 15 Jun 2009 - 5:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate articleCurrent Article Ratings:
| Patient / Public: |  |
4.41 (17 votes) |
| Health Professional: |  |
3 (1 votes) |
| Article Opinions: | 0 posts |
Human Genome Sciences (HGS) has reported continuation data from a Phase II study of BENLYSTA™ (belimumab, formerly LymphoStat-B®) showing sustained improvement in patients with active systemic lupus after four years of treatment. The data was presented at the EULAR 2009 scientific meeting in Copenhagen, Denmark.
Early results from a 52-week Phase III study of BENLYSTA™ are expected to be announced in July and results from a 76-week study are scheduled to be released in November.
BENLYSTA™ is being co-developed and commercialized by HGS and GlaxoSmithKline (GSK).
The HGS website has the full release about this additional Phase II data.
Source
Lupus Foundation of America
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Lupus headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
